Related Experiment Video
Updated: Jul 14, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Understanding eNOS for pharmacological modulation of endothelial function: a translational view
Branko Braam1, Marianne C Verhaar
1Div. Nephrology of the Dept. of Medicine, CSB 11-107, University of Alberta, Edmonton, AB, Canada. branko.braam@ualberta.ca
Current Pharmaceutical Design
|June 23, 2007
Summary
Endothelial nitric oxide synthase (eNOS) dysfunction reduces nitric oxide (NO) bioavailability, contributing to atherosclerosis. Cardiovascular risk factors exacerbate this, impacting NO production and signaling pathways.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Biochemistry
Background:
- Endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO), crucial for vascular health.
- Diminished NO bioavailability is a hallmark of endothelial dysfunction and atherosclerosis.
- Cardiovascular risk factors significantly impact eNOS function and NO signaling.
Purpose of the Study:
- To review the effects of cardiovascular risk factors on NO production by eNOS.
- To identify key mechanisms of reduced NO bioactivity in cardiovascular disease.
- To highlight areas of eNOS functionality requiring further investigation.
Main Methods:
- Literature review and analysis of existing research on eNOS function.
- Examination of pathophysiological states related to cardiovascular risk factors.
- Synthesis of knowledge on NO production, breakdown, and signaling.
Main Results:
- Four primary causes of diminished NO bioactivity identified: decreased eNOS expression/activity, eNOS uncoupling, enhanced NO scavenging, and impaired NO signaling.
- Reactive oxygen species (ROS) and eNOS uncoupling are significant contributors to reduced NO bioactivity in cardiovascular diseases.
- Specific eNOS modifications like palmitoylation, myristoylation, and phosphorylation remain understudied in high-risk conditions.
Conclusions:
- Understanding eNOS regulation is critical for addressing endothelial dysfunction.
- Targeting ROS production and eNOS uncoupling presents therapeutic opportunities.
- Further clinical assessment of eNOS aspects and development of therapeutic strategies are needed.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:21Pharmacodynamics: Overview and Principles
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...